LivaNova wins FDA premarket approval for neuromod for sleep apnea
March 19, 2026
LivaNova (Nasdaq: LIVN)+ announced today that it received FDA premarket approval (PMA) for its aura6000 neuromodulation system for sleep apnea.
LivaNova (Nasdaq: LIVN)+ announced today that it received FDA premarket approval (PMA) for its aura6000 neuromodulation system for sleep apnea.
There is a promising new drug for the rare disease mastocytosis, which is associated with skin lesions, among other things. Researchers at the University of Basel have now been able to use artificial intelligence to quantitatively measure for the first time the extent to which it reduces skin lesions.
Nia Therapeutics announced today that it received FDA breakthrough device designation for its Smart Neurostimulation System (SNS).
A study has found that precise application of radio waves can change the activity of brain cells in ways that could counter neurological conditions.
Now, research published in ACS Central Science could help health care professionals non-invasively diagnose bacterial infections, using breath-based tests.
A new X-ray imaging technique could transform how hospitals analyze tissue samples, potentially speeding up diagnoses and improving outcomes for patients, shows a new study led by UCL researchers. The technology, developed in collaboration with the Memorial Sloan Kettering Cancer Center, Rigaku Americas and Creatv MicroTech, Inc., produces crisp 3D maps of biological tissue without cutting or staining samples, a significant improvement on the conventional process used in histopathology—the process of examining tissue to study, diagnose and treat diseases, particularly cancer.
Duke Health researchers show that a quick, outpatient nasal swab can pick up early biological changes linked to Alzheimer’s, even before thinking and memory problems appear.
Now, scientists at UC San Francisco have developed a method to precisely reprogram these cancer-fighting cells directly inside the body, potentially eliminating the manufacturing process, cost, and waiting time that has kept this life-saving therapy out of reach for many patients around the world.
CINCINNATI, March 18, 2026 /PRNewswire/ — Mammotome, a Danaher company, announces FDA Clearance of two innovations for MR-guided breast biopsy: the Mammotome Prima™ MR Dual Vacuum-Assisted Breast Biopsy System – the industry’s first solution designed to be positioned in the MRI scanner room at the patient’s side – and the HydroMARK™ Plus Breast Biopsy Site Marker for MR, engineered for exclusive use with the Mammotome Prima™ system universal targeting set. Following a successful debut of the Mammotome Prima™ MR system in Europe, both products will be introduced to U.S. clinicians at the 2026 Society of Breast Imaging (SBI) Symposium. By bringing the device directly into the scanner room, the Mammotome Prima™ MR system enhances clinician coordination, streamlines communication, and helps maintain consistent focus on the patient throughout the procedure.
MiniMed Flex™ is about half the size of the previous generation MiniMed™ 780G system, and features the SmartGuard™ adaptive algorithm to automatically adjust and autocorrect insulin delivery in real-time